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Summary 
More than one third of the world’s population is infected with at least one helminth, among 
which schistosomiasis and trichuriasis are highly prevalent. The control of schistosomiasis 
relies heavily on the treatment of people living in endemic areas with praziquantel. 
Praziquantel is currently the only available antischistosomal drug and 28 million patients are 
treated every year, which leads to a high drug pressure on schistosomes. The low efficacy on 
the juvenile stage of Schistosoma and the risk of development of drug resistance urges the 
development of an alternative treatment. The current chemotherapy of trichuriasis, using two 
benzimidazoles albendazole and mebendazole, results in unsatisfactory treatment outcomes. 
The co-administration of the two drugs cures more trichuriasis patients than the drugs 
administered separately. Also the co-administration of albendazole with the rediscovered 
trichuricidal drug oxantel pamoate is a promising treatment. In order to apply these co-
administrations on the large scale, safety has to be assured. 
The objectives of this thesis were to advance the development of antischistosomal 
drugs by conducting structure-activity relationship studies and by defining new 
pharmacophores for lead optimization. Moreover, we aimed to determine the safety of two co-
administrations (albendazole plus oxantel pamoate, and albendazole plus mebendazole) by 
studying their preclinical in vitro and in vivo drug-drug interactions. 
 
Three compound sets were investigated for antischistosomal activity by testing them first 
against the larval and adult stage of S. mansoni, followed by a cytotoxicity determination to 
finally evaluate the in vivo efficacy in the chronic S. mansoni mouse model. 
The first set tested consisted of five different synthetic peroxide classes: bridged 1,2,4-
trioxolanes, bridged 1,2,4,5-tetraoxanes, tricyclic monoperoxides, silyl peroxides, and 
hydroxylamine derivatives. The trioxolanes, tetraoxanes, and the tricyclic monoperoxides 
showed high in vitro activities in the low micromolar to nanomolar range. None of the 
compounds revealed significantly high drug efficacy in vivo. The highest efficacy was 
achieved by the trioxolane class displaying a worm burden reduction (WBR) of 44%. Since 
low solubility of the peroxides was noted and assumed to be a major limiting factor for drug 
efficacy, the peroxides were next packed into a cyclodextrin complex. However, the WBRs 
were unchanged. Further lead optimization of peroxides should aim to synthesize compounds 
with higher aqueous solubility. 
In a further project, we assessed the antischistosomal activities of MMV665852 
analogs to identify new pharmacophores. N,N’-diarylureas, N-phenyl benzamides, and N-aryl 
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phenylcarbamates revealed high and fast in vitro activity at concentrations in the low 
micromolar to the nanomolar range within few hours of drug exposure. For high activity, the 
presence of a conjugated ring system on both sides of the structures was essential. The highest 
WBRs were observed with a N-phenyl benzamide (66%) and a N,N’-diarylurea (43%). For 
this drug set, we investigated the “drugability” of the compounds using in silico and in vitro 
tools, testing physico-chemical parameters, solubility, permeability through the intestinal 
wall, and metabolic stability. Solubility appeared to be the main reason for low “drugability” 
of the compounds. Also this set of molecules demonstrated the necessity of the compound to 
have drug-like features. Therefore, it is recommended to apply a “structure-bioavailability-
activity”-based drug design and screen flow. 
Several marketed cancer drugs contain the N,N’-diarylurea or N-phenyl benzamide 
structures. Additionally, cancer drugs are believed to target drug action present in 
schistosomes and in humans. For these reasons, a cancer drug library of 114 compounds was 
tested for antischistosomal activity. Eleven drugs demonstrated in vitro activity below 10 µM, 
of which two demonstrated in vivo activity (trametinib: 64% WBR, vandetanib: 48% WBR). 
Future studies might involve multiple administrations of the drugs to simulate their long half-
lives in humans, which are short in the mouse, or the assessment of the drugs’ influence on 
schistosome development, with which cancer drugs were suggested to interfere. 
 
The potential for drug-drug interactions of albendazole plus mebendazole and albendazole 
plus oxantel pamoate was assessed using two approaches: first, using an in vitro metabolic 
assay, assessing the inhibition of Cytochrome P450 (CPY), and second, comparising 
pharmacokinetic parameters after applying co-administrations or monotherapy to rats.  
The in vitro CYP inhibition assay showed only interaction against CYP1A2. In more 
detail, this interaction was presented by a 2.6-fold decreased IC50 value, when the enzyme was 
simultaneously exposed to albendazole and oxantel pamoate compared to separate exposures.  
For analysis of the plasma concentrations from the in vivo study, a High Pressure 
Liquid Chromatography (HPLC) method with UV detection was developed for oxantel 
pamoate, albendazole sulfoxide and sulfone (the two major metabolites of albendazole), and 
mebendazole and validated according to FDA guidelines. No interaction between albendazole 
and oxantel pamoate was observed in vivo, presumably due to low bioavailability of oxantel 
pamoate. However, a moderate interaction was observed in the disposition of mebendazole. 
Mebendazole co-administered with albendazole resulted in a significantly increased area 
under the plasma curve (AUC) (3.5-fold increase) and a maximal plasma concentration (Cmax) 
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(2.8-fold increase). However, the observed interaction might not apply to humans, since the 
plasma levels observed in humans, after the standard treatment dosages are ten to thirty times 
lower than the levels we observed in rats. It is further not known what role the species 
differences of the quantitative biotransformation of benzimidazole plays. Therefore, further 
safety studies on co-administration albendazole plus mebendazole in healthy humans might be 
needed to confirm the safety of the regimen. A safety study of the co-administration 
albendazole plus oxantel pamoate may only be considered, if tests for absorption and 
bioavailability of oxantel pamoate indicate exposure of the body to oxantel pamoate. 
 
In conclusion, the projects of antischistosomal drug discovery identified new active 
pharmacophores and provided evidence for the hypothesized antischistosomal activity of 
cancer drugs. The pharmacokinetic safety evaluation detected a potential interaction when 
albendazole and mebendazole are co-administered. 
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1.1 Burden and control of helminth infections 
More than one third of the world’s population (2.5 billion of 6.7 billion in 2008) is infected with 
at least one helminth. People living in poor conditions in subtropical and tropical areas are most 
affected by helminthiases [1]. The mortality rates of many neglected tropical diseases are not 
high. However, the diseases are characterized by lengthy periods of suffering and often by a 
lifetime of disablement [2]. 
The World Health Organization (WHO) recommends an approach to overcome the 
global impact of neglected tropical diseases through five interventions: 1) innovative and 
intensified disease management; 2) preventive chemotherapy, vector ecology and management; 
3) veterinary and public-health services; 4) provision of safe water, sanitation and hygiene [3]. 
In 2010, preventive chemotherapy reached about 35% of those who needed treatment, 
at least once during a 12-month period. This is more than 700 million people, and the current 
approach aims to accelerate preventive chemotherapy programs and to widen their range [4]. 
The implementation of mass drug administration urges the scientific and global health 
community to better understand the pharmacology of the commonly used drugs, to better 
monitor and understand drug resistance, and to conduct drug discovery to have alternative 
treatments if resistance occurs [5]. 
Schistosomiasis and trichuriasis are two helminth infections belonging to the neglected 
tropical diseases. Approximately 207 million people suffer from an infection with Schistosoma 
spp., a blood-dwelling trematode. Trichuriasis is an intestinal nematode infection, caused by 
the soil-transmitted helminth Trichuris trichiura, and affects approximately 604 million people 
worldwide [1].  
In spite of their global health significance, research and development of novel drugs for 
schistosomiasis and trichuriasis has been limited. For instance, there is only one 
antischistosomal drug on the market, which is a perilous situation in case of emergence of drug 
resistance. Moreover, a better knowledge about pharmacokinetics of promising drug co-
administrations against trichuriasis is desired. In general, both diseases are in need for increased 
research on better treatment options. 
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1.2 Schistosomiasis 
1.2.1 Epidemiology and life cycle 
Schistosomiasis is caused by flukes (trematodes) of the genus Schistosoma. The main species 
pathogenic for humans are S. mansoni (prevalent in Africa, Middle East, and the Americas), 
S. japonicum (East Asia), and S. haematobium (Africa and Middle East). Less  common are 
S. mekongi (Mekon River basin), S. intercalatum and S. guineesis (west and central Africa) 
(Figure 1) [6]. 
 
Figure 1: Global prevalence of infections with Schistosoma spp. infecting humans 
[6] 
 
People become infected via cutaneous penetration of exposed skin in schistosome-
infected waters (Figure 2). In the human body, schistosomes mature from the larval stage 
(schistosomula) in the blood stream to the juvenile stage in the lung, and finally to the adult 
stage in the mesenteric and portal veins (hepatic schistosomiasis), or the veins of the bladder 
(urinary schistosomiasis, exclusively caused by S. haematobium). The maturation to the adult 
stage takes approximately 5-7 weeks [7]. Adult schistosomes have a long live span of 3-10 years 
on average, and up to 40 years [6], during which male and female worms in copula produce 
hundreds of eggs per day [8]. The eggs migrate throughout the body and cause inflammation - 
the actual cause of morbidity. Eggs that reach the gastrointestinal (GI) tract are excreted via the 
feces and hatch after contact with freshwater to miracidia. This aquatic form locates snails using 
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chemotaxis and infects them. Within the snails, miracidia undergo several rounds of asexual 
proliferation to develop into cercariae. After 6 weeks, the cercariae are shed into the water and 
locate humans (the final host), which they infect percutaneously [7]. 
 
Figure 2: Life cycle of S. mansoni, S. haematobium, and S. japonicum 
Paired adult worms (A) produce eggs (B), which are excreted into water and transform 
into miracidia (C). In the snail host (D), miracidia multiply to cercariae (E), which 
penetrate people standing in infectious waters [7].  
 
1.2.2 Disease and symptoms 
There are two manifestations of schistosomiasis: acute and chronic. Acute symptoms can be 
caused by the percutaneous penetration of cercariae, which results in urticaria, also known as 
“swimmer’s itch”. The migrating schistosomula lead to a hypersensitivity reaction few weeks 
after infection, also called Katayama fever, which can manifest as cough, head ache, and fever 
[7]. The chronic stage is responsible for most of the disease burden, which occurs once the 
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worms have matured to adult fluke pairs and are releasing eggs. Proteolytic enzymes released 
during egg migration provoke inflammatory reactions in the surrounding tissues. The symptoms 
of urinary and intestinal schistosomiasis are non-specific, such as anemia, malnutrition, bloody 
urine or stool, and impaired childhood development. Moreover, urinary schistosomiasis is a risk 
factor for bladder cancer [6].  
 
1.2.3 Diagnosis and treatment 
Schistosomiasis can be diagnosed by microscopic or molecular detection of viable eggs in the 
stool, or urine. These techniques are however limited by low sensitivity and heterogeneous 
distribution of the eggs in the excretes [6]. Of the microscopic methods, FLOTAC showed 
higher sensitivity in stool samples of S. mansoni patients than the most widely used Kato-Katz 
fecal thick smear method [9]. The serological detection of antibodies against schistosome 
infection is useful for diagnosing schistosomiasis in travelers after their return, but less useful 
for diagnosing people living in endemic areas, since antibodies remain in the blood circulation 
after elimination of the infection [6]. Diagnosis using polymerase chain reaction (PCR) to 
multiply schistosome-specific DNA sections, is very sensitive and selective, but is generally 
less applicable in endemic areas due to lack of specialized facilities and personnel [10]. A rapid 
diagnostic test detects circulating cathodic or anodic antigens (CCA) in urine of S. mansoni 
patients. The test showed the sensitivity of triple Kato-Katz diagnosis, without cross-reactivity 
to S. haematobium [11]. A test based on circulating anodic antigens (CAA) is under 
development. 
Chronic schistosomiasis of all species can be treated with praziquantel. For 
S. haematobium and S. mansoni, the standard treatment used in preventive chemotherapy 
programs is a single oral dose of 40 mg/kg body weight; for S. japonicum and S. mekongi it is 
60 mg/kg. Praziquantel is, however, inefficacious against premature schistosomes, and 
therefore not adequate for treatment of acute infections [6]. Hence, a second dose of 
praziquantel may be recommended after the parasites have fully developed. The cure rate of 
praziquantel is 60 to 90%, and is often overestimated due to the low sensitivity of diagnostic 
tools [12].  
Every year, hundreds of millions of tablets are distributed to people at risk of infection. 
This is possible through private-public partnerships (PPPs). For example, in 2004, MedPharm 
donated 14 million praziquantel tablets, and Merck KGaA pledged 200 million tablets in the 
years 2008 to 2017 [13]. In 2012, 28 million people were treated with praziquantel [14]. 
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No vaccine against schistosomiasis is available to date. However, a few candidates 
showed 50 to 70% worm burden reduction in animal models, and some progressed to early 
phase clinical trials. Efficacy in humans has yet to be proven. Additionally, decoding the 
genomes of schistosomes in the past years, may allow the generation of recombinant proteins, 
e.g. of surface or intestinal proteins, that will facilitate and thus probably accelerate the 
development of a vaccine [15]. 
 
1.2.4 Recent research for new treatments 
Since praziquantel is the only treatment available against schistosomiasis, and emergence of 
drug resistance cannot be excluded, research for new antischistosomals is needed [12].  
During the last two decades, derivatives of the antimalarial artemisinin (product of 
Artemisia annua) have been studied on schistosomes intensively. Since most of this work was 
conducted at Swiss TPH, findings on these drugs are presented in greater detail. Several 
artemisinin derivatives demonstrated antischistosomal activity, such as artemether [16], the 
fully synthetic ozonides (or trioxolanes) [17],[18], trioxaquines [19], dioxolanes [20], bridged 
tetraoxanes and tricyclic monoperoxides [21]. Among these, OZ418 demonstrated high and 
species-independent drug efficacy in the S. mansoni and the S. haematobium mouse model, 
displaying worm burden reductions (WBRs) of 80% and 86%, respectively [18]. Current lead 
compounds at the Swiss TPH are presented in Table 1. The most recent structure-activity 
relationship studies of the peroxides demonstrated high in vitro activities of a bridged tetraoxane 
after a 72-hour exposure (IC50 of 0.1 µM against larval stage, and IC50 of 0.3 µM against adult 
stage) and a WBR of 75%. The in vitro activities of a tricyclic monoperoxide were slightly 
lower (IC50 of 14.4 µM against larval stage, and IC50 of 11.8 µM against adult stage), however, 
showed higher in vivo activity with 83% WBR [21].  
Both the antimalarial and the antischistosomal mechanism of action of artemisinin and 
the peroxidic derivatives is most probably due to an interference of the drugs’ peroxide with 
heme polymerization, leading to hemozoin accumulation, which is toxic to the parasites [22]. 
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Table 1: In vitro and in vivo activities of molecules with promising antischistosomal activity 
studied at the Swiss TPH, compared with praziquantel 
Molecular structure IC50 larval 
S. manoni 
[µM] 
IC50 adult 
S. mansoni 
[µM] 
SI WBR [%] Ref. 
Current drug of choice: praziquantel 
 
2-(Cyclohexylcarbonyl)-2,3,6,7-
tetrahydro-4H-pyrazino[2,1-
a]isoquinolin-4-one  
2.21 0.11 >9601 >90%2 
[21]1 
[31]2 
Artemisinin-inspired synthetic peroxides 
 
Bridged 1,2,4,5-tetraoxane 
0.1 0.3 5.7 75.4 
[21] 
 
Tricyclic monoperoxide 
14.4 11.8 4.9 83 
 
 
 
Ozonide OZ418 (R = OCH2COOH) 
Not done >2003 Not done 80%4 
[32]3 
[18]4 
Mefloquine 
Quinoline    
6.65 12.75 0.35,6 735 
[23]5 
[33]6 
IC50: Concentration of 50% drug effect 
SI: Selectivity index (IC50 cytotoxicity divided by IC50 of adult schistosomes) 
WBR: Worm burden reduction 
8 
 
 
Mefloquine is another antimalarial drug found to possess antischistosomal activity. It is 
an interesting candidate due to its seemingly species-independent and developmental stage-
independent activity. Briefly in more detail, mefloquine revealed an IC50 of 6.6 µM against 
S. mansoni larvae in vitro. The adult stage of S. mansoni and S. japonicum was less susceptible, 
with IC50 values of 12.7 µM and 16.4 µM, respectively. Artificially infected mice that were 
treated with 200 mg/kg mefloquine per body weight showed a decreased S. mansoni worm 
burden of 73%, or S. haematobium burden of 81%. S. japonicum had an EC50 of 53 mg/kg on 
the juvenile stage [23]. The few clinical trials showed inconsistent results, thus, more studies 
are needed to describe the extent of efficacy in schistosomiasis patients. It might be worth 
highlighting that mefloquine treatment raises concern about development of resistance against 
Plasmodium falciparum, which is co-endemic in areas where schistosomiasis persists [24]. 
The fact that Schistosoma shares mechanisms of action with P. falciparum lead to the 
screen of a compound library assembled by the Medicines for Malaria Venture (MMV), the so 
called MMV Box. The library consists of 400 drug-like compounds with attested in vitro 
activity against P. falciparum [25]. Indeed, the screen identified several lead candidates for 
which lead optimization would be worth perusing (Table 1). MMV665852 was most promising 
due to its activity and chemical attractiveness. In vitro activity was high with an IC50 value of 
Table 1: continued 
Molecular structure IC50 larval 
S. manoni 
[µM] 
IC50 adult 
S. manson
i [µM] 
SI WBR [%] Ref. 
MMV Box 
 
 
N,N’-diarylurea (MMV665852) 
4.7 0.8 40 53 
[26] 
 
2,3-dianilinoquinoxaline 
>33.3 Not done 7.1 41 
IC50: Concentration of 50% drug effect 
SI: Selectivity index (IC50 cytotoxicity divided by IC50 of adult schistosomes) 
WBR: Worm burden reduction 
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4.7 µM against the larval and 0.8 µM against the adult stage of S. mansoni. However, the WBR 
was only moderate with 53% [26]. 
Other great efforts have been made in antischistosomal drug discovery over the last 
decades, screening large compound libraries of new [27],[28] or marketed drugs [29]. 
Furthermore, a wide assortment of natural products with antischistosomal activity has been 
identified [30].  
 
1.2.5 The need for new antischistosomal drugs 
Since its appearance on the market in 1975, after almost half a century of praziquantel use, and 
millions of people being treated annually [14], no other drug has been marketed for 
antischistosomal treatment [34],[28]. Indeed, praziquantel eliminated the urgent need for 
antischistosomal drug research, and replaced the then widely used antischistosomal 
chemotherapies. Praziquantel had clearly advantages over oxamniquine, which was only 
efficacious against S. mansoni [35], and for which drug-resistance had been reported [36], and 
also antimony-tartrate, which was given intravenously [35], or metrifonate, which is less widely 
applicable than praziquantel, since it is only active against S. haematobium [35].  
There is a general discussion about whether new drugs against schistosomiasis are 
needed. Some stakeholders are not satisfied with only one drug on the market, mainly due to 
anticipation of drug resistance [5],[12], but also due to its moderate cure rate and inactivity 
against juvenile schistosomes [23]. Others, however, do not expect drug resistance, due to 1) 
the long life cycle of schistosomes; 2) refugia, where susceptible strains do not experience 
pressure of mass drug administrations; 3) biological inferiority of schistosomes with 
experimental praziquantel-resistance compared to praziquantel-susceptible worms; and 4) the 
dependence on the host’s immune system in praziquantel’s mode of drug action [37]. 
Undoubtedly, the various efforts to discover new antischistosomals, as described above, 
demonstrate the general desire to find alternatives to praziquantel. Since no other product has 
been marketed yet [38], research efforts should be continued. 
  
10 
 
1.3 Trichuriasis 
1.3.1 Epidemiology and life cycle 
Trichuris trichiura causing trichuriasis or human whipworm infection, infects an estimated 600 
to 700 million people and is one of the most prevalent helminth infections [1],[39] next to the 
other soil-transmitted helminths Ascaris lumbricoides (1 billion infected) and hookworm 
infections (600 million infected) [39]. T. trichiura prevails in tropical and subtropical areas all 
over the globe (Figure 3). Approximately 50% of all trichuriasis cases are found equally in sub-
Saharan Africa, East Asia and the Pacific Islands; 40% are found in Latin America and the 
Caribbean, South Asia, or India. China, and middle, east and north Africa host the least 
T. trichiura number of infections [39]. 
 
 
Figure 3: Global prevalence of trichuriasis [40] 
 
Infection occurs via ingestion of T. trichiura eggs. The larvae hatch and settle preferably 
in the cecum - in stronger infections also in the colon and rectum - where they develop into 
adult worms within 12 weeks (Figure 4) [39]. The thin anterior part of the parasite is anchored 
to approximately one third of its length in the epithelial cells of the intestinal lumen. In this 
“syncytial tunnel”, the cuticle of the worm is in contact with the cytosol of the ruptured 
epithelial cells. The posterior part, however, is located in the lumen of the GI tract [41]. Adult 
female worms lay eggs, which are released into the environment via fecal excretion by the 
human [39]. 
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Figure 4: Life cycle of T. trichiura [42] 
 
1.3.2 Disease and symptoms 
Light infections persist unrecognized. At site of parasite attachment, inflammation occurs and 
can lead to colitis. An array of symptoms can result from colitis, such as chronic abdominal 
pain, diarrhea, anemia, impaired growth, finger clubbing, and in more serious cases chronic 
dysentery and rectal prolapse. Most intense infections occur in children aged 5-15 years. 
Whether the decline of intensity and frequency of infections in adulthood is due to changes in 
exposure, acquired immunity, or both, remains controversial [39]. 
 
1.3.3 Diagnosis and treatment 
The presence and intensity of T. trichiura infection can be examined with light microscopy by 
determining the number of eggs per gram feces, using the Kato-Katz fecal thick smear, the 
McMaster method, or FLOTAC [43]. Light infections can be detected by concentration of the 
eggs with formalin ethyl acetate sedimentation [39]. 
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Trichuriasis, like the other soil-transmitted helminth infections, is treated with 
albendazole or mebendazole in the frame of  preventive chemotherapy programs [44]. Around 
30% of children at risk for acquiring soil-transmitted helminth infections are reached in these 
programs, using single-dose albendazole or mebendazole [45]. However, clinical trials 
conducted between 1960 and 2007 showed unsatisfying treatment outcomes. Albendazole cured 
on average merely 28% of infected people, and mebendazole 36% [46].  
No vaccine is available against trichuriasis yet. One candidate showed promising result, 
expelling all worms from mice, 35 days after application [15]. 
 
1.3.4 Recent research for new treatments 
Despite the urgent need for better chemotherapies against trichuriasis [47], only few potential 
drugs have been investigated in recent years.  
The antiprotozoal drug nitazoxanide emerged and disappeared again as a drug 
candidate against trichuriasis. In vitro activities against the larval (IC50<1µg/ml) and adult stage 
(IC50=12.9 µg/ml) of T. muris were promising, and the in vivo WBR was moderate (56% after 
100 mg/kg p.o.) [48]. Unfortunately, the efficacy could not be translated to humans [49]. 
Similarly, monepantel was an interesting candidate due to its broad-spectrum activities 
against intestinal parasites [50], and its availability on the veterinary drug market. However, 
lack of in vitro and in vivo activity in T. muris infection models prevented further investigations 
[51].  
Emodepside is a semi-synthetic product from the fungus Mycelia sterilia, living in the 
leaves of Camellia japonica. Emodepside demonstrated efficacy against trichuriasis in naturally 
infected livestock and domestic animals [52], as well as experimental Trichuris infections [53]. 
Bayer Animal Health has released a combination of emodepside with toltrazuril (Procox®) to 
rid dogs from Trichuris vulpis, other nematodes, and coccidian [54]. Procox® is highly 
efficacious in dogs (100%) [55]. In 2014, the Drugs for Neglected Diseases Initiative (DNDi) 
signed an agreement with Bayer Health Care to develop emodepside for treatment of 
onchocerciasis patients [56]. Once preclinical and Phase I testing has been completed the 
trichuricidal properties of emodepside should be tested in phase 2 trials. 
Several benzimidazole anthelmintics for veterinary use were active in clinical trials, 
such as oxibendazole, fenbendazole, flubendazole, and thiabendazole. The various dose 
regimens used in the different clinical trials showed inconsistent cure rates between 17 and 
100%. Further interesting candidates, which come from the veterinary field are doramectin, 
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milbemycin oxime, and moxidectin. Indeed, drug repurposing reveals a way to accelerate and 
at the same time lower the costs of anthelmintic drug discovery and development [29].  
The effect of trans-cinnamaldehyde, a component of cinnamon (Cinnamonum verum), 
on Trichuris suis was discovered this year. In vitro tests showed a more than 50% mortality rate 
of larvae (L1), when exposed to 30 µM for 2 hours. Trans-cinnamaldehyde orally applied to 
pigs did not reduce the worm burden. The authors suspect the compound to be well absorbed 
into the blood stream, thus lowering the concentration in the intestine where the parasite resides. 
Therefore, altering the oral formulation might improve in vivo efficacy [57]. 
Papain, a cysteine protein kinase from the papaya fruit (Carica papaya), demonstrated 
high efficacy in the T. suis pig infection model. A single dose of 450 µmol resulted in a WBR 
of 98%, which was higher than the treatment with 400 mg (1.5 mmol) albendazole, whicht 
resulted in a WBR below 39%. The investigators want to proceed with the development of a 
formulation with the prospects of applying papain in humans [58]. 
Another promising strategy for developing better treatments is the use of combination 
of existing drugs [5]. This was demonstrated with combinations of albendazole plus 
mebendazole, where the cure rate was 54%, compared to single albendazole (15%) and 
mebendazole (20%) [59]. Another combination, albendazole plus ivermectin, showed superior 
efficacy in multiple studies [60],[61],[62]. 
Last but not least, oxantel pamoate demonstrated efficacy and safety in trichuriasis 
patients, and is described in more detail in the section below. 
 
1.3.5 Oxantel pamoate, a drug of clinical relevance against trichuriasis 
Oxantel pamoate is being studied as co-administration with albendazole, aiming to provide a 
broad-spectrum antinematodal therapy. In trichuriasis patients, oxantel pamoate plus 
albendazole resulted in higher cure and egg reduction rates (69% and 99%, respectively), than 
albendazole plus ivermectin (28% and 95%, respectively), or albendazole plus mebendazole 
(8% and 52%, respectively). Moreover, oxantel pamoate plus albendazole co-administration 
did not lead to increased side effects [63]. 
The profile of oxantel pamoate is summarized in Table 2. Oxantel pamoate is best 
known in combination with pyrantel pamoate and praziquantel as a broad-spectrum deworming 
medication for cats and dogs [64]. In dogs, the egg reduction rate is 98%, after the  
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Table 2: Profile of oxantel pamoate  
Chemical structure 
 
 
Chemical group Tetrahydropyrimidine  
Year of entry into market 1966  [35] 
Clinical relevance In combination with pyrantel presents effect against 
multiple intestinal helminths: Ascaris, Enterobius, 
hookworms, Trichuris 
[75] 
Countries in which 
oxantel pamoate-pyrantel 
pamoate are registered 
Columbia [68] 
Peru [68] 
Philippines [68] 
Other anthelmintic 
tetrahydropyrimidine 
derivatives 
Pyrantel pamoate: Ancylostoma, Ascaris, Enterobius, 
Necator, Trichinella, Trichostrongylus; horse, pig, and 
ruminant nematodes; horse cestodes 
[75] 
 
Morantel: Ruminant nematodes  [75] 
Pharmacokinetic 
parameters in humans 
Absorption: Low 
Tmax: 2-4 h post-administration 
Elimination: 7% urinary 
Total elimination: 12 h post-administration 
[69] 
 
Pharmacokinetic in dogs Absorption: Negligible [66] 
Veterinary usage In combination with pyrantel pamoate and praziquantel 
as broad-spectrum deworming drug for cats and dogs 
[64] 
In vitro activities against 
helminths 
T. muris L1 IC50: 0.08 µM  [76] 
T. muris L4 IC50: 3.9 µM [77] 
A. ceylanicum L3 and adult IC50 : >150 µM [77] 
N. americanus L3 IC50: >150 µM 
N. americanus adult IC50: 19.5 µM 
[77] 
In vivo activities against 
helminths 
T. muris in mice ED50: 4.7 mg/kg [77] 
T. suis in swine: 4-5 mg/kg expelled >99% of T. suis [67] 
Mechanism of action Agonist of the N-subtype cholinergic receptor [71] 
Mode of action Interference with acteylcholin-neurotransmission 
paralyzes the worm, leading to expulsion by the host’s 
bowel movement 
[35] 
Non-anthelmintic 
bioactivities 
Reduces bacterial biofilm of Porphyromonas gingivalis 
by inhibiting the fumarate reductase (IC50=2.2 µM). 
[72]  
Reduces the heme biosynthesis by stabilizing the 
HsPBGS hexamer quaternary structure (IC50=18 µM).  
[74] 
Analytical methods 
published 
Oxantel pamoate and pyrantel pamoate from tablets 
using HPLC-UV 
[70] 
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prescribed dose (Dolpac®: 20 mg/kg oxantel, 5 mg/kg pyrantel, 5 mg/kg praziquantel) [65]. 
The absorption of oxantel after oral administration to dogs is negligible [66].  
Oxantel pamoate also demonstrated high efficacy in the T. suis swine model. After a 
dose of 4 to 5 mg/kg more than 99% of T. suis were eliminated [67]. 
An oxantel pamoate product also exists for human use, however, only in Columbia, 
Peru, and the Philippines [68], although, it is currently not produced in these countries. The 
product is combined with pyrantel pamoate and prescribed against Trichuris trichiura, 
Enterobius vermicularis, Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus, 
Trichostrongylus orientalis, and Trichostrongylus colubriformis. The absorption through the 
intestinal wall is low. The maximal plasma concentration (Cmax) is reached approximately 2-4 
hours after oral application, and about 7% of the dose is found in the urine. Most of the drug is 
excreted from the body 12 hours after application [69].  
Beside the information of the package, no data on the pharmacokinetics of oxantel have 
been published so far (date of information search: 05.11.2015). This has the consequence, that 
almost no quantitative analytical methods are available. Only one method using high pressure 
liquid chromatography (HPLC) and UV detection has been published in 1988, describing the 
quantification of oxantel and pyrantel in oxantel-pyrantel tablets [70]. 
On the molecular level, oxantel interferes with acetylcholine receptors [35]. More 
precisely, oxantel is an N-subtype cholinergic agonist. Levamisole and pyrantel on the other 
hand are agonists of the L-subtype cholinergic receptor. Therefore, the combination of oxantel 
and pyrantel were proposed to have therapeutic advantages, covering N- and L-subtypes, and 
thus increasing the spectrum of action and reducing the potential for development of drug 
resistance [71]. 
Other bioactivities were found for oxantel pamoate. Oxantel disrupts biofilm 
development of the oral bacterium Porphyromonas gingivalis with a minimal inhibitory 
concentration (MIC) of 125 µM. The target enzyme is fumarate reductase, which has an 
important role in the fermentation of amino acids. Fumarate reductase is inhibited 
at an IC50 of 2.2 µM [72]. The growth of other anaerobic bacteria, such as Helicobacter pylori 
and Campylobacter jejuni, are also inhibited, but to a lesser extent (MIC >750 µM) [73].  
Oxantel was found to be an inhibitor of the human porphobilinogen synthase (HsPBGS) 
with low activity (IC50=18 µM). HsPBGS is an essential enzyme involved in heme biosynthesis. 
Stabilization of the lower active hexamer structure of HsPBGS, opposed to the higher active 
octamer, reduces HsPBGS activity, resulting in reduced heme biosynthesis. This can implicate 
toxicities such as lead poisoning [74]. 
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1.3.6 The need for assessing pharmacokinetics and drug-drug interactions of promising 
co-administrations against trichuriasis 
Co-administered therapies could be a solution for higher efficacy and a wider range of efficacy 
against intestinal nematodes [5]. Most promising partner therapies are albendazole with 
ivermectin [60],[62], mebendazole [59], or oxantel pamoate [63]. So far, safety studies 
regarding drug-drug interactions and pharmacokinetic parameters have only been conducted for 
albendazole plus ivermectin [78],[79]. Therefore, assessing drug-drug interactions and 
pharmacokinetic parameters for albendazole plus mebendazole and albendazole plus oxantel 
pamoate is desired. 
Drug-drug interactions can occur, when one drug alters the other drug’s rate of 
elimination, leading to reduced efficacy or emergence of side effects [80]. After absorption 
through the intestinal wall, xenobiotics typically undergo a phase I metabolism, during which 
molecules are oxidized, reduced, or hydrolyzed to more hydrophilic molecules. Hydrophilicity 
is favorable for quick renal excretion. The main family responsible for phase I metabolism is 
Cytochrome P450 (CPY) [80]. Around half of the marketed drugs are converted by CYPs, 
mainly by CYP3A4 [81]. After phase I metabolism, or directly after absorption, molecules 
undergo typically phase II metabolism. Phase II metabolism involves conjugations of large 
hydrophilic molecules, such as glucuronides and sulfates, to further facilitate renal excretion 
[80]. 
Albendazole’s metabolism has been studied intensively. After oral administration, 
albendazole is quickly metabolized to the active sulfoxide metabolite and the inactive sulfone 
metabolite by the flavin-containing monooxygenase and CYPs. CYP4A3, and to a smaller 
extent CYP1A2, are involved in albendazole sulfoxide formation. CYP1A2, however, is 
strongly involved in the biotransformation of albendazole sulfoxide to albendazole sulfone [82]. 
In plasma and urine, mainly the metabolites are found, whereas albendazole can only be found 
in trace amounts [83]. Mebendazole is also excessively metabolized by the first-pass effect, 
however into inactive molecules [83]. Reduction by the CYP-independent carbonyl transferase 
was suggested to be the main metabolic pathway for mebendazole [84]. The absorption of 
oxantel pamoate is low and only 7% is excreted via the kidney [69]. Nothing is known about 
potential metabolic pathway of oxantel (date of information search: 06.11.2015).  
In vitro assays are widely used to predict drug-drug interactions [85]. For instance, CYP 
subspecies can be tested for drug inhibition to reveal potential metabolic interactions between 
drugs [86]. Figure 5 shows possible pathway of in vitro CYP-inhibition incorporated into the 
basic pharmacokinetic processes: absorption, metabolism, excretion (distribution is not 
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depicted). In the scheme, oxantel pamoate, mebendazole, and albendazole are depicted and it is 
hinted how their pathways could interfere. 
Besides in vitro predictions, in vivo studies on pharmacokinetics are essential to form a 
more accurate picture of the processes in humans, and steer decisions for further drug 
development steps [85]. 
 
 
Figure 5: Simplified pathway of drugs in the body and possible CYP drug-
drug interactions of ABZ, MBZ, and OxP 
The absorbed portion of albendazole (ABZ) is metabolized by phase I reactions. 
CYP3A4 and 1A2 are involved (based on literature, as depicted by black arrows). 
Mebendazole (MBZ) is not known for metabolism by CYP, but CYP-interfere in 
the presence of ABZ or ABZSO cannot be excluded (improbable interaction, as 
depicted by dashed arrows). Little oxantel pamoate (OxP) is absorbed into the 
body. Interactions with CYP are not known (depicted by dotted arrows).  
 
  
18 
 
1.4 Aims of the dissertation 
As mentioned above, new antischistosomal drugs are needed on the market as an alternative to 
praziquantel. Furthermore, potential drug-drug interactions of promising co-administrations 
should be assessed. Therefore, the aim of this dissertation was to identify novel antischistosomal 
drugs and to elucidate the pharmacokinetics of co-administered treatments against trichuriasis. 
Following objectives were conducted to achieve the overall project aim: 
 
· Progress the optimization of artemisinin-inspired peroxides in antischistosomal drug 
discovery 
 
· Determine the potential of the hit compound MMV665852 of the MMV Box as a new 
antischistosomal class  
 
· Explore the antischistosomal potency of a library of approved cancer drugs, of which 
several present a promising molecular structure or mechanism of action 
 
· Determine in vitro CYP drug-drug interactions of oxantel pamoate and benzimidazole 
combinations 
 
· Develop and validate an HPLC/UV-Vis method for simultaneous detection of 
albendazole’s metabolites (albendazole sulfoxide and sulfone), mebendazole, and 
oxantel in plasma 
 
· Compare promising co-administrations against trichuriasis (albendazole plus oxantel 
pamoate; albendazole plus mebendazole) to single drug treatments in the rodent model, 
using the developed HPLC/UV-Vis method, for pharmacokinetic profiling of the co-
administrations 
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6.1 Antischistosomal drug discovery 
With praziquantel as the only drug available against schistosomiasis and the high drug 
pressure on Schistosoma, development of drug resistance is anticipated; thus, research for new 
antischistosomal drugs is needed [1],[2]. This pressing situation promoted the evaluation of 
three compound sets for antischistosomal activity: Set 1: Lead optimization of synthetic 
peroxides; Set 2: Pharmacophore characterization of MMV665852 (N,N’-diarylurea) analogs; 
and Set 3: Exploration of a cancer drug library.  
 
6.1.1 Synopsis of three drug sets tested for antischistosomal activity 
The investigation of the three drug sets for antischistosomal activity resulted in the following 
findings: 
 
Set 1:  Strengthened evidence that artemisinin-inspired synthetic peroxides (bridged 
tetraoxanes, tricyclic monoperoxides, and bridged trioxolanes, also known as 
ozonides) have excellent antischistosomal activity. 
 
Set 2: Identification of N,N’-diarylurea, N-phenyl benzamide, and N-aryl 
phenylcarbamate derivatives as potent novel chemical classes with in vitro and in 
vivo antischistosomal activity. 
 
Set 3:  Discovery of marketed cancer drugs with in vitro and in vivo activity. The study 
findings supported the hypothesis of cancer drugs to be potential antischistosomal 
drugs through their inhibition of protein kinases. 
 
The antischistosomal activities of hit structures of the three sets are summarized in Table 3. 
When screening compounds of Sets 1 and 2, the most striking observation was the 
discrepancy between in vitro and in vivo activities. Both sets were potent, demonstrating in 
vitro activities below 1 µM. Set 2 was even fast acting, reaching IC50 values below 1 µM after 
1 hour of incubation. However, in the mouse model, the worm burden reductions (WBRs) for 
hits in Sets 1 and 2 were not higher than 44% and 66%, respectively. 
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Table 3: Features of the hit compounds of all three sets tested 
Compound IC50 larval 
S. mansoni 
[µM] 
IC50 adult 
S. mansoni 
[µM] 
SI WBR 
[%] 
Other charac-
teristics 
Set 1: Peroxides      
 
 
Trioxolane (cpd 30) 
2.2 4.2 1.6 44 
Low solubility 
 
Tricyclic monoperoxide (cpd 44) 
2.7 4.4 5.7 27 
OO
O O
 
Tetraoxane (cpd 6) 
0.9 1.8 0.5 
not 
done 
Set 2: MMV665852 analogs      
 
N-phenyl benzamide (cpd 38) 
0.2 0.6 4.9 66 
Fast acting; 
low solubility; 
moderate to 
good predicted 
pharmacoki-
netics 
 
N,N’-diarylurea (cpd 2) 
1.3 0.7 5.4 43 
 
 
N-aryl phenylcarbamate (cpd 45) 
0.5 0.7 2.9 0 
Set 3: cancer drugs      
 
Trametinib 
4.6 4.1 <0.1 64 
Slow activity; 
high 
bioavailability; 
long half-live 
 
 
 
 
 
Vandetanib                 
0.9 9.5 0.8 48 
IC50: Concentration of 50% drug effect; SI: Selectivity index; WBR: Worm burden reduction 
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Set 3 exhibited a different pattern of activity. In vitro, the cancer drugs were less 
potent than the previous two sets, displaying higher IC50 values and a longer time until activity 
was observed (24-72 hours). Yet, the in vivo results were in the same range as Sets 1 and 2, 
with WBRs of 63% and 48% for the two hit cancer drugs (trametinib and vandetanib). In the 
screening of Set 3, we considered plasma protein binding as a potential activity-reducing 
factor. Indeed, repeating the adult S. mansoni in vitro assay with the physiological 
concentration of serum albumin demonstrated a loss of activity for 8 out of 14 molecules. 
Testing the influence of plasma protein binding on antischistosomal activity might be worth to 
be included in the screen flow, or solely used as additional compound characterization of 
promising candidates, for instance, when attempting to discriminate two compounds 
otherwise very similar. 
Regarding cytotoxicity, Set 1 contained several molecules (mainly tetraoxanes) 
displaying toxicity in the nanomolar to low micromolar range, whereas Set 2 remained at low 
micromolar values. Also Set 3 revealed significant cytotoxic values ranging between <0.37 
µM (lowest value tested) and 32 µM (data not published). Clearly, these results are not 
surprising considering the anti-prolific nature of cancer drugs. When looking at their relative 
cytotoxicity, all three sets laid in the same range with selectivity indexes (i.e. 
IC50cytotoxicity/IC50antischistosomal activity) between 1 and 10. This demonstrates that also marketed 
drugs, although compelled by safety regulations, show in vitro toxicity. Thus, in vitro toxicity 
should be interpreted in the context of other available information. 
Important to mention is the fact that Sets 1 and 2 showed (microscopically observed) 
solubility issues, which might have led to the moderate efficacies. For Set 2, we investigated 
potential reasons for the low in vivo efficacy by testing the following parameters: Number of 
violations of the rule of 5 (described below), solubility, and permeability through the 
intestinal wall. The tests indicated low solubility (<3 µM for all compounds tested) to be the 
reason for low absorption, since only dissolved molecules can cross the intestinal wall, and 
would therefore lead to low drug exposure of the schistosomes. The other parameters 
predicted moderate to good bioavailability for the majority of compounds.  
As mentioned above, the in vivo efficacy in all sets was moderate to low. In Sets 1 and 
2, we attempted to improve the compounds’ in vivo efficacies by increasing intestinal 
absorption via two different methods. In vivo candidates of Set 1 were packed into a complex 
using β-cyclodextrin, a commonly used method to enhance drug solubility [3]. Unfortunately, 
no improvement in drug efficacy could be observed. In the case of Set 2, an oily formulation 
(olive oil, polyethylene glycol, water) was used for the in vivo lead compounds. The 
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compounds did dissolve better in the oil-based formulation, however, drug efficacy was not 
increased (data not published). Indeed, the addition of hydrochloric acid to simulate digestive 
juices led to compound precipitation in the formulation. This might be the reason for 
insufficient freely available drug for absorption. 
Regarding future lead optimization of Set 1, I would add hydrophilic side chains to the 
three lead scaffolds, the trioxolanes and tricyclic monoperoxides, as well as to the more toxic 
tetraoxanes. I would not yet declare tetraoxanes as too unselective, since structure 
optimization may lead to higher selectivity. Cytotoxicity is merely a model estimating toxicity 
in humans and should be evaluated in context with other factors, such as in vitro activities and 
existing information about drug safety (e.g. LD50 values of marketed drugs). In future lead 
optimization studies, I would incorporate a screen for “drugability”. The goal would be to find 
a balanced drug profile of antischistosomal activity, selectivity, and bioavailability. In the 
same manner, future lead optimization of Set 2 should consist of more hydrophilic derivatives 
of the three potent classes: N,N’-diarylureas, N-phenyl benzamides, and N-aryl 
phenylcarbamates. 
In contrast to Sets 1 and 2, two marketed drugs of Set 3, despite their moderate in vitro 
schistosomicidal activity, revealed WBRs similar to top candidates in Sets 1 and 2. Both hit 
drugs of Set 3 (trametinib and vandetanib) have an exceptionally long half-live in humans (4.2 
days and 19 days, respectively), while the half-live in mice is shorter (3 days, and 28 hours, 
respectively) [4]. As these drugs exert their activity rather slowly (72 hours), using multiple 
dosing in the mouse to prolong the drug exposure of the worms might simulate the in-human 
situation more accurately, and result in higher efficacy. 
Furthermore, since trametinib and vandetanib target protein kinases, a class involved 
in important biological mechanisms in helminths (e.g. growth and gonad maturation) [5], the 
effect of the drugs on schistosome maturation should be assessed as well. Last, we have seen 
strain differences of in vitro results earlier. Once, when we screened the MMV box (Liberian 
strain) and compared the results with the MMV box screen at the London School of Hygiene 
and Tropical Medicine (Puerto Rican strain) [6]; and at another occasion, when we compared 
the in vitro activity of imatinib (an antischistosomal cancer drug) with earlier published 
results (Luiz Evangelista strain) [4]. Therefore, it is recommendable to test any new 
chemotype on various Schistosoma strains and species to assess the spectrum of 
antischistosomal activity. 
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6.1.2 Relevance of physico-chemical properties and “drugability” 
During my work, I applied several assays for pharmacokinetic compound profiling to either 
explain observed in vitro/in vivo discrepancies, or as part of the screening cascade. Indeed, 
since the introduction of combinatorial chemistry and high throughput screens, a trend toward 
lower solubility and less permeability of clinical candidates evolved [7]. Dr. Christopher 
Lipinski investigated the physico-chemical properties of orally administered drugs and created 
the famous rule of 5. The rule describes drug-likeness according to physico-chemical 
properties as follows: the molecular weight should be below 500 g/mol, the octanol-water 
partition coefficient (LogP) should not be greater than 5, and the number of hydrogen bond 
donors and acceptors should not exceed 10 or 5, respectively. All numbers are multiples of 
five, which gave the rule’s name. The numbers are a rule of thumb, and thus, many orally 
available molecules violate the rule of 5 [8]. Similarly to the rule of 5, molecules have been 
classified according to their solubility and permeability into four types using the 
Biopharmaceutics Classification System (BCS) [9]. BCS 1 represents molecules with high 
solubility and high permeability, BCS 2 low solubility and high permeability, BCS 3 low 
permeability and high solubility, and BCS 4 low solubility and permeability. The 
classification serves for instance as guidance for bioavailability and bioequivalence studies, as 
well as for dose formulations and improvement of drug efficacy [10]. The BCS is illustrated 
in Figure 6, including in vitro drug activity, and exemplified with the three drug sets tested. 
BCS 1 substances are without doubt the preferred molecules in drug discovery. 
However, as mentioned above, modern drug discovery screens using target-based drug design, 
without screening first for “drugability”, inherently select for more lipophilic molecules. This 
trend was examined using clinical candidates at Merck and at Pfizer between the years 1960 
and 2000. Merck screened compounds first for bioavailability before proceeding to target-
activity studies. Pfizer on the other hand screened bioavailability after the target-activity 
studies. The evolution of clinical candidates at Merck showed unchanging compound 
lipophilicity (LogP). In contrast, the clinical candidates at Pfizer were increasingly lipophilic, 
meaning lower solubility of the compounds [11].  
Indeed, also anthelmintic drug discovery might be prone to select for lipophilic 
molecules, since drug uptake predominantly happens via passive transport into the worms 
[12] . 
In general, screening and designing molecules for optimal antischistosomal activity 
and selectivity is not enough to predict in vivo efficacy. Hence, it is advisable to incorporate 
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physico-chemical calculations and pharmacokinetic predicting tools in the existing screen 
flow.  
When applying ADME (absorption, distribution, metabolism, elimination) assays 
before target activity determination, it might be worth to use multiple screening models for 
the determination of “drugability” to prevent “false-positive” and “false-negative” results in 
the drug discovery process [14]. 
 
 
 
Figure 6: The position of the three drug sets tested according the 
Biopharmaceutics Classification System (BCS), and in vitro antischistosomal 
activity. 
Set 1 showed low solubility, but high antischistosomal activity. Their permeability 
through the intestinal wall is unknown. Set 2 showed low, but high and fast activity. 
The predicted permeability was moderate to good. Set 3 was less active, with a slow 
onset of action. Bioavailability for the hit compounds is 90-100%. 
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Some in silico and in vitro predictive assays were performed during the present research on 
antischistosomal drugs. They are described below, and summarized and evaluated for further 
usage in Table 4. 
Physico-chemical properties. Of utmost importance is compound solubility. 
Compounds should be synthesized with consideration for an optimal solubility index, and 
tested for aqueous solubility. We tested the in vitro solubility by dissolving the compound in 
an aqueous phase, removing the precipitated fraction after 15 hours, and analyzing the amount 
of compound in solution [15]. Another method to predict solubility is the determination of 
LogP, which LogP should be below 5, and can be determined in vitro [8], or in silico [16]. In 
our study, we assessed rule of 5 with a freely downloadable in silico tool [15],[17]. 
Permeability and metabolic pathway assays. Cell-based assays are widely used to 
simulate the passage of small molecules across the intestinal wall (caco-2 cells) [18], or to 
assess their hepatic metabolism (hepatocytes) [19]. Newer, non-cell based tools were 
developed for easier handling and leave more freedom in choosing assay parameters (e.g. pH, 
or testing of cytotoxic substances). We performed for instance the parallel artificial membrane 
permeation assay (PAMPA), which simulates penetration through the small intestinal wall by 
using a donor well (containing drug), acceptor well (initially containing no drug), and a 
membrane (can be coated with lipids to simulate barriers, such as the intestinal wall, or the 
blood-brain barrier) separating the two wells from each other. After incubation, the drug 
concentration in the acceptor well represents the passive drug absorption [20]. Assays using 
an artificial lipid membrane demonstrated correlation with caco-2 results and can therefore 
serve as a valid alternative to cell-based assays [14]. Likewise, non-cell based kits for 
determining metabolic stability are widely used. Microsomes, for instance, are extracted 
fractions of hepatocytes containing the endoplasmatic reticulum, which expresses CYP 
metabolic enzymes [21]. A microsomal stability assay was established with a master student 
in the frame of her master thesis. The assay was able to determine the clearance of in vivo 
candidates. Furthermore, for the determination of CYP inhibition, recombinant isomers of 
CYP can be purchased [22]. Recombinant CYP isozymes most involved in drug metabolism 
(CYP1A2, 2C9, 2C19, 2D6, and 3A4), were used in our work for estimation of drug-drug 
interactions of promising co-administrations as treatment of trichuriasis. 
In our study of Set 2, it became apparent, that prediction of bioavailability is only one 
piece of the puzzle and does not guarantee antischistosomal activity since the rule of 5 was 
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Table 4: Current assays at Swiss TPH used in the framework of this thesis  and evaluation of assays used for antischistosomal drug research – 
experience and recommendations 
 
 
Target 
identification
Drug 
discovery
Preclinical 
studies
Clinical 
studies 
phases I-III
Approval
Phase IV 
surveillance
Lead discovery Lead optimization In vivo studies 
Current Assays   
- Development of in vitro assays 
- Screening of drug sets (20-2000 molecules) using                                  
phenotypic readout 
- SAR studies for characterization of pharmacophore/lead compounds 
- Estimation of drug selectivity using a L6 rat myoblast cytotoxicity assay 
- Influence of blood components on activity 
- In vivo studies (proof of concept on infected mice) 
- In depth toxicity studies 
- Dose-dependent efficacy (e.g. EC50 determination) 
Tested Assays   
Assay Rule of 5 
Purpose In silico bioavailability 
estimation. 
Advantage No costs. Simple procedure.  
Medium to high throughput. 
Disadvantage Active transport systems are 
neglected. 
Remarks Can be applied prior to 
molecule synthesis. 
Suggestion for 
maintenance of 
assay tested 
Recommended for molecule 
design in SAR studies. 
 
Assay Aqueous solubility 
Purpose Solubility determination. Screen for BCS 1 molecules. 
Advantage Simple procedure.  
Medium to high throughput.  
Spectrometric readout. 
Disadvantage Partly specialized equipment needed. Costly. 
Remarks - 
Suggestion for 
maintenance of 
assay tested 
Appropriate solubility is essential for PK and PD. 
Sharing this tool in the units working on drug discovery 
might be a cost-effective solution.  
 
Assay β-cyclodextrin complexation 
Purpose Improvement of water-solubility to 
improve absorption. 
Advantage Established method in drug 
development. 
Disadvantage - 
Remarks Highly lipophilic molecules can still get 
stuck in the intestinal wall. 
Suggestion 
for 
maintenance 
of assay 
Specialized partners need to prepare 
the complexes. Hit compounds might 
benefit from complexation. 
 
 Assay PAMPA 
Purpose Prediction of passive transport across the intestinal wall 
for estimation of drug absorption. Screen for BCS 1 
molecules. 
Advantage Medium to high throughput. 
Assay conditions are flexible. 
Correlation to caco-2 cell assay. 
Disadvantage LC/MS readout. 
Specialized equipment needed; thus relatively high 
costs. 
Remarks Does not predict active transport. 
Suggestion for 
maintenance of 
assay 
Sharing this tool in the units working on drug discovery 
might be a cost-effective solution.  
 
Assay Oil-based formulation 
Purpose Increase the amount of dissolved 
compound in the formulation 
Advantage Easy procedure. 
Disadvantage - 
Remarks Influence of fatty food drug on 
absorption is usually unknown. Gastric 
juices might lead to precipitation after 
all. 
Suggestion 
for 
maintenance 
of assay 
Can be applied in special cases, e.g. if 
positive food interactions are implied. 
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Assay Serum albumin binding 
Purpose Assess the influence of serum proteins on 
antischistosomal activity 
Advantage Conventional microscopic readout 
Disadvantage - 
Remarks - 
Suggestion for 
maintenance of 
assay 
Serum albumin could be added in the culture medium in 
adult S.mansoni assays, or as an extra screening filter 
for in vivo candidates. 
 
 
 Assay Microsomal stability 
Purpose Assess the metabolic phase I stability 
Advantage Validated kits are available 
Disadvantage Low throughput. LC or LC/MS readout. 
Remarks - 
Suggestion for 
maintenance of 
assay 
Can be used for small sets, such as in vivo candidates 
or lead compound determination in SAR studies. 
 
 
 Assay CYP450 drug-drug interaction 
Purpose Test for enzyme inhibition or induction  
Advantage Validated kits are available. Spectrometric readout. 
Disadvantage Slightly costly. Reagents are described to be light-and 
freeze-thaw sensitive. 
Remarks - 
Suggestion for 
maintenance of 
assay 
Recommended for novel co-administered combinations, 
or drug candidates which need a more detailed drug 
profiling. 
 
 
Assays to consider using   
  Assay Snap-shot PK 
Purpose Picture plasma levels in animal 
models 
Advantage Close to true picture in vivo 
Disadvantage Very low throughput 
Remarks - 
Suggestion for 
maintenance of 
assay 
Recommended for compounds of 
special interest. 
 
Table 4: continued 
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true in most cases and the PAMPA assay predicted moderate to good passive absorption. The 
low solubility of the compounds was most probably the restriction for drug efficacy.  
In conclusion, I recommend including physico-chemical calculations in the drug 
screen. Online tools are available and involve therefore no costs. Moreover, the metabolic 
stability assay using hepatic microsomes was established in our laboratory and will help to 
prevent in vivo studies with compounds displaying too fast clearance. The solubility assay 
and the PAMPA assay are useful tools to evaluate compound solubility or absorbance, 
respectively. In case the behavior of compounds requires more evidence, assessment of the 
plasma profile after oral application of the compounds (snap-shot pharmacokinetic profiling) 
might be useful. 
I strongly endorse the establishment of these or equivalent techniques in the screen 
flow. Including these screening steps will achieve higher drugability of in vivo candidates, 
and should steer toward higher antischistosomal drug efficacy. From an ethical point of view, 
the elimination of “undrugable” compounds before in vivo tests is in agreement with the 3R 
rule (reduce, refine, replace), which promotes the reduction of laboratory animal usage.  
 
6.1.3 Importance of public-private and academic partners 
Public-private partnerships have a pivotal role in the control of neglected tropical diseases 
(NTDs). In 2009, half a billion drug doses were donated for treatment of NTDs in over 80 
endemic countries. This was the result of over 320 million partnerships with non-
governmental development organizations [23]. Over the next few years, approximately 2 to 3 
billion dollars will be needed to realize the ambitious aim of controlling and eliminating 
NTDs [24]. The increased funding opportunities through national governments and 
philanthropic institutions (e.g. Rockefeller and Gates Foundations) allowed higher budgets for 
research and development for new drugs, which are urgently needed [25]. 
Indeed, our work also clearly profited from valuable existing public-private and 
academic partnerships. For instance, the Medicines for Malaria Venture (MMV) donated the 
MMV box for our precursor study of Set 2, and selected compounds for the structure-activity 
relationship study of Set 2. MMV also provided us with valuable pharmacokinetic and 
toxicity information about the compounds. In this respect, the support by Dr. Thomas 
Spangenberg was of great value. Also the cancer drug library of 114 compounds was donated 
by a non-profit organization, the Developmental Therapeutics Program (DTP) of the US 
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National Institute of Health (NIH). This project could only be realized by the donation of the 
drugs, since the purchase of 114 compounds would have been beyond our budget.  
Furthermore, the evaluation of Sets 1 and 2 was done in tight collaboration with 
academic partners. For instance, all peroxides of Set 1 were synthesized by Dr. Alexander 
Terent’ev and colleagues of the N.D. Zelinsky Institute of Organic Chemistry, Russia. For Set 
2, we received support from Dr. Jonathan Vennerstrom of the Department of Pharmaceutical 
Sciences of the University of Nebraska Medical Center, USA, who confirmed uncertainties 
about chemical questions. In addition, for Set 2, we performed an array of pharmacokinetic-
relevant measurements in collaboration with Dr. Beat Ernst and Philipp Dätwyler at the 
Department of Pharmaceutical Sciences of the University of Basel. 
In general, partners can support research by providing ideas, expertise, and critical 
input, which are all pivotal for high quality research. 
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6.1.4 Continuation of the projects 
I think that all three projects of antischistosomal drug discovery should be continued because 
they exhibited good to excellent in vitro activities, as well as in vivo efficacy. Concluding 
from the discussion above, I would proceed as follows: 
 
Future short-term steps 
 
· Include solubility as a feature for drug design 
· Use in silico tools for ADME predictions in the drug screen 
· Use serum albumin in adult S. mansoni assay to assess potential loss of activity of in 
vivo candidates  
· Test hit compounds for antischistosomal activity in other schistosome species (S. 
haematobium, S. japonicum) or other S. mansoni strains 
· Assess the effect of multiple oral doses for trametinib and vandetanib upon 
experimental S.mansoni-infection 
 
Future long-term steps 
 
· Incorporate bioavailability as a feature in the screening cascade. Academic or private 
partners might provide support in this endeavor 
· Use snap-shot plasma profiling for compounds of special interest 
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6.2 Trichuriasis drug research 
Due to poor treatment outcomes of trichuriasis patients with the drugs of choice albendazole 
(cure rate: 28%) and mebendazole (cure rate: 36%), a more efficacious treatment is needed 
[26]. Two co-administration regimens showed superior drug efficacy in trichuriasis patients: 
albendazole plus oxantel pamoate (cure rate: 69%) [27] and albendazole plus mebendazole 
(cure rate: 54%) [28]. Both co-administrations could be quickly approved for use, since all 
three compounds are already safely used in humans worldwide, however, not in these 
combinations [29],[30].  
In general, a better understanding of the relationship between pharmacokinetic 
parameters and efficacy of anthelmintics against gastrointestinal nematodes should be 
developed to maximize treatment outcome [31].  
I conducted preclinical safety studies of the above-mentioned co-administrations, and 
carried out preliminary experiments to determine the compartment responsible for 
trichuricidal efficacy (findings to be published). 
 
6.2.1 Main findings and interpretation of the safety assessment of the two co-
administrations albendazole plus oxantel pamoate, and albendazole plus 
mebendazole 
The CYP inhibition study assessed the potential for the co-administered drugs to use the same 
metabolic pathway in vitro. Interference of the mutual metabolism can lead to adverse events 
in the organism treated [21]. Secondly, the co-administrations were assessed in the rodent 
model to observe potential interactions.  
 
In vitro: Moderate CYP interaction was observed in CYP1A2, with the combination 
albendazole plus oxantel pamoate (2.6-fold compared to separate inhibitions). 
 
In vivo: Co-administration of albendazole plus mebendazole led to a significantly 
increased area under the curve of mebendazole (3.5-fold; p=0.02), compared to 
single mebendazole treatment. 
 
The in vitro CYP inhibition assays showed solely interaction at CYP1A2, which was slightly 
more inhibited (2.6-fold increase; IC50 of 3.1 µM) when albendazole and oxantel pamoate 
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were combined as opposed to the separate inhibitions. Since the absorption of oxantel is low 
[32],[33], drug-drug interactions of hepatic enzymes are unlikely to occur. 
When tested in vivo, the albendazole plus oxantel pamoate co-administration showed 
no signs of drug-drug interaction; the pharmacokinetic parameters (area under the curve 
[AUC], maximal concentration [Cmax], time at maximal concentration [tmax], half-life [t1/2]) 
were almost identical to the parameters of albendazole as single treatment. Oxantel pamoate 
could not be quantified in any sample, meaning that the plasma levels were below 0.4 µg/ml, 
which was the lower limit of quantification (LLOQ) of the analytical method. Roughly 
calculated, that would correspond to a bioavailability below 0.025%, provided that the entire 
dose applied (100 mg/kg body weight of the rat) would be absorbed and not metabolized 
(blood volume calculated according to H. B. Lee and M. D. Blaufox [34]). Therefore, the 
absence of drug interactions is not surprising. 
Despite declarations about low bioavailability observed in humans [33] and dogs 
[32],[35], no precise numbers of the bioavailability of oxantel pamoate are available. To 
confirm this common knowledge, I would endorse a small study in humans to generate sound 
evidence about the bioavailability of oxantel pamoate. Also, determining the in vitro 
absorption of oxantel might be of interest for estimation of drug exposure of the liver. 
Absorption could be predicted for instance with the above-mentioned PAMPA assay. If 
oxantel pamoate will be absorbed in vitro and detected in humans, the need for 
pharmacokinetic drug-drug interaction studies with the co-administration of albendazole plus 
oxantel pamoate should be evaluated. 
Albendazole co-administered with mebendazole on the other hand showed slight 
interaction, expressed in elevated mebendazole levels. Drug interaction can be defined as a 
change of the AUC by 25% [36]. Therefore, the statistically significant 3.5-fold increase of 
mebendazole’s AUC upon co-administration (p=0.02), can be regarded as a result of drug-
drug interaction. Also Cmax was significantly higher (2.8-fold; p=0.02) than after single 
treatment. Other pharmacokinetic parameters (tmax and t1/2) remained unchanged. 
Since the CYP inhibition study did not show any interaction between albendazole and 
mebendazole, the reason for the higher AUC might be a result of non-CYP enzymes, such as 
inhibition of the carbonyl transferase, and/or the flavin-containing monooxigenase. The first 
hypothesis was suggested as the main pathway for mebendazole biotransformation [37]; 
however, albendazole is not known for biotransformation via the carbonyl transferase [38]. 
The latter is a major pathway for albendazole, but has not yet been characterized for 
mebendazole metabolism [39]. Another reason for drug-drug interaction might be the 
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inhibition of efflux mechanisms from the blood stream into the intestine. In more detail, in 
rats, the efflux protein p-glycoprotein was suggested to transport albendazole sulfoxide across 
the intestinal wall into the intestine [40]. If mebendazole and albendazole sulfoxide compete 
for the same efflux mechanism, plasma level of one or both drugs could potentially increase 
upon co-administration. 
Generally, CYP interactions with the isozyme 3A4, which is the main metabolic 
pathway for albendazole [38], seem unlikely. A study in 16 healthy volunteers assessed 
interactions of albendazole or mebendazole with ritonavir, a highly potent CYP3A inhibitor. 
Ritonavir (200 mg/kg) did not affect the disposition of albendazole (400 mg) or mebendazole 
(1000 mg) upon a single exposure to the co-administrations. The investigators suggested co-
administrations with other CYP3A inhibitors most likely to be safe as well [41]. 
Undoubtedly, the results of our in vivo studies in rats are only an indication about the 
situation in humans. A diverging factor is for instance the difference in plasma concentrations. 
In our study, the AUC of a single albendazole treatment with 100 mg/kg resulted in an AUC 
of 63.8 µg/ml*h in rats, whereas in humans, a 400 mg dose resulted in 5.4 µg/ml*h [41]. 
Similarly, mebendazole applied to rats at 100 mg/kg led to an AUC of 5.9 µg/ml*h, whereas 
in humans, a 1000 mg dose lead to an AUC of 0.2 µg/ml*h [41]. The drug exposure in 
humans, using standard doses, was clearly lower than in our experimental interaction studies. 
Thus, interactions that occurred in rats might not translate to humans. 
Furthermore, species differences in benzimidazole metabolism should be considered 
[42]. For example, unequal ratios of ABZSO’s (-) and (+) enantiomers were observed: in 
humans the ratio is 20:80, whereas in rat it is 59:41, respectively [38], which might change the 
pattern of drug interactions. 
These pharmacokinetic studies were a first step to assess drug safety. Without doubt, 
in vitro and in vivo experiments do not replace clinical studies. One can argue, that co-
administration of well-known and proven-to-be-safe drugs are most likely safe when applied 
together. Moreover, co-administration therapies are not dangerous per se; many people in the 
industrialized world are subject of polypharmacy. Hospitalized people older than 65 years old, 
and diagnosed with hypertension, for instance, take in average 4.4 different drugs a day [43]. 
Nevertheless, since we do not know the precise toxic threshold of the drugs, it is difficult to 
estimate the impact of elevated plasma levels on toxicity and adverse events. Furthermore, we 
do not know how pathologies of helminth infections influence the pharmacokinetics of the 
drugs, whether they lead to or exacerbate drug interactions.  
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With respect to safety uncertainties still remaining and species difference in 
benzimidazole biotransformation, I would conduct a study with healthy volunteers and 
patients in endemic areas. Elucidation of the pharmacokinetics of albendazole plus 
mebendazole co-administration in humans might ultimately rule out drug-drug interactions. 
 
6.2.2 Gastrointestinal metabolic interactions and the determination of the 
compartment responsible for drug activity against T. muris 
After reviewing safety considerations, efficacy considerations of aforementioned drug co-
administrations will be discussed. The co-administrations showed improved efficacy as 
opposed to their single treatments. Is the efficacy of albendazole and mebendazole co-
administration improved due to metabolic drug-drug interaction in the gastrointestinal (GI) 
tract? Also in the GI tract, albendazole is exposed to biotransformation into its sulfoxide 
metabolite [44]. Intestinal nematodes take up drugs from exposure in the intestinal lumen 
[13]. Since albendazole seems to be more relevant for drug efficacy than albendazole 
sulfoxide [12], a change in albendazole biotransformation might impact the treatment 
outcome. Mebendazole has no active metabolite [42]. Therefore, inhibition of mebendazole 
metabolism would lead to a higher drug exposure of the intestinal worms, hence, probably 
resulting in higher efficacy. To date, no study has tested the inhibition or induction of 
albendazole and mebendazole biotransformation in the GI tract (date of information search: 
18.11.2015). Analyzing the GI tract content and mucosa for oxantel pamoate, mebendazole, 
albendazole, albendazole sulfoxide, and albendazole sulfone might provide information about 
intestinal metabolism and interactions. 
Currently, the compartment responsible for drug activity against Trichuris has not 
been identified. The answer is not trivial, since Trichuris’ anterior is embedded to one third in 
the “syncytial tunnel”, and two thirds of the posterior end is freely laying in the lumen of the 
GI tract [45]. Studies with T. suis suggested parasitic drug uptake via the bloodstream, since 
the concentration of drug found in the worms correlated best with blood concentrations of 
oxibendazole, fenbendazole’s major metabolite, and less with concentrations observed in the 
GI tract [46]. On the other hand, drug diffusion through the cuticle (nematodes) or the 
tegument (trematodes) is the predominant way of drug entry, rather than oral ingestion [12]. 
Identification of the compartment responsible for drug activity is crucial for drug research 
against trichuriasis, and should therefore be further investigated. 
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Currently, a project addressing the identification of the compartment responsible for 
trichuricidal efficacy is ongoing. Preliminary studies demonstrated intensive metabolism of 
albendazole in the GI tract to albendazole sulfoxide, without further metabolism to the sulfone 
metabolite (Figure 7). Only little drug quantities could be found in the mucosa. 
 
  
 
Figure 7: Distribution of albendazole, albendazole sulfoxide, and albendazole 
sulfone.  
Albendazole was applied orally to one mouse at 100 mg/kg body weight. The dissection 
time point was 4 h post-treatment. Red: intestinal mucosa; blue: intestinal content; green: 
plasma 
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Mebendazole and oxantel were predominantly quantified in the GI tract content with 
low concentrations in the mucosa (Figure 8). The relatively low concentrations of 
mebendazole (only 4-times higher than the strongly metabolized albendazole) indicate 
metabolism in the GI tract. In contrast, oxantel seems to experience less biotransformation 
than the other drugs analyzed, concluded from the high levels in the GIT content.  
 
  
Figure 8: Distribution mebendazole and oxantel.  
Mebendazole and oxantel pamoate were applied orally to mice (each drug n=1) at 100 
mg/kg body weight. The dissection time point was 4 h post-treatment. 
Red: intestinal mucosa; blue: intestinal content; green: plasma 
 
Further tests should monitor drug distribution at different time points to estimate the 
full exposure of the parasite to the active anthelmintics. Of further interest will be the 
relationship between the drug concentrations observed within the worms and in the different 
compartments. Correlation of concentrations might then identify the compartment responsible 
for drug efficacy and serve as a marker for efficacy.  
For instance, in a project with bachelor students, we analyzed the in vitro drug uptake 
into T. muris (Figure 9): albendazole was found in highest quantity, followed by 
mebendazole, and oxantel demonstrated least entry. Oral ingestion seemed not to be the major 
route of uptake for any of the drugs, since dead and alive worms incubated in drug-containing 
medium displayed comparable amounts of drug in their tissue. Analyzing the worms 
concomitantly to the drug distribution might shed light onto the question about which 
compartment correlates with the drug amounts observed in Trichuris. 
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Figure 9: Uptake of oxantel, albendazole (ABZ), and mebendazole (MBZ) 
into T. muris in vitro. 
Alive or dead adult T. muris (two measurements, each of n=30 worms) were 
incubated in 10 µM drug for 24 hours. After thorough rinsing, the worms were 
ground and drugs were extracted with methanol, followed by HPLC-UV analysis. 
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6.2.3 Next steps in trichuriasis drug research 
In vitro and in vivo data, as well as hints from clinical trials about potential interactions of 
albendazole and mebendazole, form a mosaic of the actual pharmacokinetics in humans upon 
co-administration. I would recommend obtaining a clear picture of the actual profile. Also 
more studies pertaining “host-parasite pharmacokinetics” are needed. The studies would 
encompass the following objective: 
 
· Confirmation of the superior efficacy of albendazole plus mebendazole co-
administration compared to other treatments. 
· Study of albendazole plus mebendazole co-administration kinetic profiles in an 
endemic area. The standard doses of 400 mg albendazole and 500 mg mebendazole 
could be applied. The influence of infections and infection intensity would be of 
interest. In this respect, patients with intestinal schistosomiasis should be included in 
the study.  
· Testing albendazole plus mebendazole in different infection models might serve as 
preliminary study, and justify aforementioned studies in patients.  
· Examination of oxantel pamoate’s bioavailability in humans. The standard dose of 
20 mg/kg could be applied, but also a higher dose, e.g. 40 mg/kg to “test the limits”. 
Goal would be to confirm the general assumption of oxantel’s negligible 
bioavailability with numbers. 
· Determination of the in vitro intestinal absorption of oxantel pamoate to estimate the 
drug exposure of the liver. 
· Evaluation of the need for a pharmacokinetic drug-drug interaction study of 
albendazole plus oxantel pamoate co-administration in humans. 
 
· Assessment of metabolism and drug-drug interaction in the GI tract. Increased 
exposure to the active drug, due to drug-drug interactions, might explain changes in 
drug efficacy. 
· Determination of the compartment responsible for drug effect using the T. muris 
mouse model. Does drug uptake into the worm happen via blood ingestion or via 
uptake through the cuticle from the GI tract? This information is important for drug 
efficacy and pharmacokinetic studies. 
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6.3 Conclusion 
The aim of the thesis was to advance anthelmintic drug research, with emphasis on structure-
activity relationship and pharmacokinetic studies. The following conclusions can be drawn 
from the results obtained. 
The two structure-activity relationship studies on S. mansoni showed high in vitro 
activities. The IC50 values were in the nanomolar range, which is hardly seen in 
antischistosomal drug discovery, close to praziquantel values. However, none of the 
compounds expressed high efficacy in the S. mansoni mouse model. ADME predictions 
suggested low solubility to be the main issue, possibly leading to low absorption. Hence, 
synthetic peroxides and the MMV665852 analogs might reveal higher activities in vivo, if the 
design of the structures aims for higher aqueous solubility. Therefore, a higher in vivo-hit rate 
might be achieved by using a “structure-bioavailability-activity”-based drug design and 
screen flow. Testing marketed cancer drugs provided first experimental data on the general 
hypothesis that the mechanism of action of cancer drugs might translate to antischistosomal 
activity. The results showed indeed activity of protein kinase inhibitors on S. mansoni. 
However, the in vivo worm burden reductions were very low to moderate. Further studies 
might involve multiple dosing of trametinib and vandetanib in mice to simulate the long half-
lives observed in humans, as well as testing their effect on schistosome development. 
The in vitro CYP inhibition studies showed slight interaction between albendazole and 
oxantel pamoate. This interaction was not observed in vivo, probably because oxantel is 
hardly absorbed. A significant interaction was observed in vivo for mebendazole, when 
mebendazole was co-administered with albendazole. Since there is not enough evidence for 
the safety of albendazole plus mebendazole co-administration, clinical trials in endemic areas 
should assess pharmacokinetic parameters of this co-administration regimen in case it will be 
used in larger scale. Additionally, the intestinal absorption of oxantel pamoate is of interest, 
and is advised to be tested in vitro. To sum up, my studies present a first insight in co-
administrations that might soon be applied for preventive chemotherapy in endemic areas. 
Ongoing projects assessing the distribution of trichuricidal drugs should be continued 
to determine the compartment in the host that is responsible for drug efficacy. This knowledge 
is crucial for drug development against trichuriasis. 
In conclusion, my projects advanced helminth drug research and development by 
identifying new chemotypes with promising activity against S. mansoni, which enriched the 
meager collection of molecules available for antischistosomal drug discovery. Moreover, the 
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pharmacokinetic evaluation demonstrated the need for safety confirmation of the albendazole 
plus mebendazole co-administration in humans. This is an important step in the process of 
developing a better treatment against trichuriasis. 
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2. “Preclinical studies on Trichuris muris: from structure-activity 
relationship to drug uptake studies” 
3. “Drug uptake of albendazole, mebendazole, and oxantel pamoate 
into T. muris and Heligmosomoides polygyrus” 
· Introducing the students to the research field, as well as to biological 
and analytical methods 
· Provide guidance and supervision for the work 
 
Dec 2014 Bachelor block course 
Giving students a taste of scientific work 
· Organize and conduct a short but interesting laboratory based 
project for students 
· Provide students with essential background information  
· Intensive assistance of their practical work and analysis of results 
  
Other work experience 
2009 - 2011 KidsLab, children’s program of the Café Scientifique in collaboration 
with the University of Basel 
Explaining scientific and political topics to 6-12-year-old children 
· Planning and executing scientific workshops for children 
  
Languages  
German Mother language 
English Proficient user, C1 (European reference; 2012)  
French Intermediate 
Italian, Spanish, 
Japanese 
Basic  
 
Software skills 
Microsoft office: Very good 
Chemstation for HPLC: Routine usage 
Prism: Basic knowledge 
Biografx, Quasar, Raptor, und Yeti (for testing target affinity in sillico): basic knowledge 
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Oral presentations at international conferences 
April 2015 “On the way to new antischistosomal drugs”, British Society of 
Parasitology Spring meeting 2015 
 
Peer-reviewed publications 
Approved oncology drugs lack in vivo activity against Trichuris muris despite in vitro activity. 
Cowan N, Raimondo A, Keiser J. 
Parasitol Res. 2016 Nov;115(11):4443-4446.  
 
In vitro and in vivo drug interaction study for two lead combinations, oxantel pamoate plus 
albendazole and albendazole plus mebendazole, for the treatment of human soil-transmitted 
helminthiasis.  
Cowan N, Vargas M, Keiser J 
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6127-33.  
 
Treatment of human and livestock helminth infections in a mobile pastoralist setting at 
Lake Chad: Attitudes to health and analysis of active pharmaceutical ingredients of locally 
available anthelminthic drugs. 
Greter H, Cowan N, Ngandolo BN, Kessely H, Alfaroukh IO, Utzinger J, Keiser J, 
Zinsstag J 
Acta Trop. 2016 May 25. pii: S0001-706X(16)30328-X.  
 
Repurposing of anticancer drugs: in vitro and in vivo activities against Schistosoma 
mansoni. 
Cowan N, Keiser J. 
Parasit Vectors. 2015 Aug 13;8:417. 
 
Elucidation of the in vitro and in vivo activities of bridged 1,2,4-trioxolanes, bridged 
1,2,4,5-tetraoxanes, tricyclic monoperoxides, silyl peroxides, and hydroxylamine 
derivatives against Schistosoma mansoni. 
Cowan N, Yaremenko IA, Krylov IB, Terent'ev AO, Keiser J. 
Bioorg Med Chem. 2015 Aug 15;23(16):5175-81.  
 
Activities of N,N'-Diarylurea MMV665852 analogs against Schistosoma mansoni. 
Cowan N, Dätwyler P, Ernst B, Wang C, Vennerstrom JL, Spangenberg T, Keiser J. 
Antimicrob Agents Chemother. 2015 Apr;59(4):1935-41 
 
Orally active antischistosomal early leads identified from the open access malaria box. 
Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, Wells TN, 
Spangenberg T, Keiser J. 
PLoS Negl Trop Dis. 2014 Jan 9;8(1):e2610 
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